Shares of Idexx Laboratories (NASDAQ:IDXX) reached a new 52-week high and low on Thursday . The stock traded as low as $226.20 and last traded at $225.10, with a volume of 11129 shares changing hands. The stock had previously closed at $223.76.
Several analysts have weighed in on IDXX shares. Zacks Investment Research lowered Idexx Laboratories from a “hold” rating to a “sell” rating in a report on Monday, April 9th. BidaskClub raised Idexx Laboratories from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 7th. Stifel Nicolaus upped their target price on Idexx Laboratories from $215.00 to $225.00 and gave the company a “buy” rating in a report on Monday, May 7th. ValuEngine raised Idexx Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Finally, Canaccord Genuity reissued a “positive” rating and issued a $215.00 target price on shares of Idexx Laboratories in a report on Monday, May 7th. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. Idexx Laboratories presently has an average rating of “Buy” and an average target price of $218.43.
The company has a debt-to-equity ratio of -12.43, a current ratio of 0.96 and a quick ratio of 0.72. The company has a market cap of $19.20 billion, a P/E ratio of 68.93, a price-to-earnings-growth ratio of 2.62 and a beta of 0.64.
Idexx Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Friday, May 4th. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.09. The business had revenue of $537.60 million for the quarter, compared to analyst estimates of $525.14 million. Idexx Laboratories had a negative return on equity of 530.24% and a net margin of 13.87%. The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.77 earnings per share. research analysts predict that Idexx Laboratories will post 4.17 earnings per share for the current fiscal year.
In related news, insider Giovani Twigge sold 1,626 shares of the stock in a transaction on Tuesday, May 29th. The stock was sold at an average price of $204.37, for a total transaction of $332,305.62. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William T. End sold 9,470 shares of the stock in a transaction on Thursday, May 10th. The shares were sold at an average price of $208.36, for a total value of $1,973,169.20. Following the sale, the director now directly owns 31,786 shares in the company, valued at approximately $6,622,930.96. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,571 shares of company stock worth $2,405,215. Corporate insiders own 2.56% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Signaturefd LLC purchased a new position in Idexx Laboratories during the first quarter worth about $105,000. Three Peaks Capital Management LLC purchased a new position in Idexx Laboratories during the first quarter worth about $108,000. Optimum Investment Advisors purchased a new position in Idexx Laboratories during the first quarter worth about $139,000. Financial Gravity Wealth Inc. purchased a new position in Idexx Laboratories during the first quarter worth about $191,000. Finally, W.G. Shaheen & Associates DBA Whitney & Co purchased a new position in Idexx Laboratories during the first quarter worth about $191,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.
About Idexx Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Receive News & Ratings for Idexx Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.